Introduction

Aurora-A protein, also known as STK15/BTAK, belong to the Aurora family of cell cycle-regulating serine/threonine kinase. Aurora-A plays a pivotal role of mitotic centrosome separation, maturation and spindle formation and stability [1,2]. At the centrosome, Aurora-A is overexpressed in the passage from G2 to M, degraded after termination of cytokinesis, and expressed at significant low levels in G1 and S passage, partly because of effective post-translational degradation through the ubiquitination machinery [3]. Overexpression and altering activity of Aurora-A leads to genomic instability, destroys the accuracy of centrosome duplication, and results in cellular transformation and malignance [4]. The evaluation of the association between single nucleotide polymorphisms (SNPs) in cell cycle regulation genes and cancer risk would be beneficial for further studies. Previous investigations demonstrated that there were two prevalent non-synonymous SNPs (F31I, rs2273535 and V57I, rs1047972) in Aurora-A coding region. F31I (rs2273535, T>A) is located on exon 3 of Aurora-A, encodes a phenylalanine → isoleucine substitution at amino acid residue 31 [5]. The other SNP, V57I (rs1047972, G>A), also in exon 3 of Aurora-A, encodes a valine → isoleucine at amino acid residue 57 [6]. Of late, Aurora-A V57I polymorphism was widely investigated for the association between the SNP and cancer risk. A number of investigations indicated that this SNP was a low protective polymorphism in carcinogenesis, particularly in breast cancer [7]. However, the results from these studies remain conflicting rather than conclusive, which may be caused by the insufficient sample sizes, different genotypic milieus and publication bias. To the best of our knowledge, there was no meta-analysis study conducted on the association of Aurora-A V57I polymorphism with cancer risk. Thus, we carried out a meta-analysis on overall eligible publications, to confirm whether the V57I polymorphism of Aurora-A was associated with cancer risk.

Aurora-A V57I (rs1047972) Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 27,269 Subjects

Weifeng Tang1*, Hao Qiu2*, Heping Jiang3*, Lixin Wang2, Bin Sun1*, Haiyong Gu1*

1 Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China, 2 Department of Microbiology and Immunology, Medical School of Southeast University, Nanjing, Jiangsu Province, China, 3 Emergency Department, Affiliated Jintan People’s Hospital of Jiangsu University, Jintan, Jiangsu Province, China

Abstract

Background: The association between Aurora-A V57I (rs1047972, G>A) polymorphism and cancer susceptibility has been widely studied. However, the results are inconsistent.

Methodology/Principal Findings: To obtain a more precise evaluation of the relationship, we performed a meta-analysis of 14 case-control studies involving a total of 11,245 cancer cases and 16,024 controls. Our results demonstrated that there was a borderline evidence of an association between the Aurora-A V57I polymorphism and the decreased risk of overall cancer in two genetic models: AA vs. GA+GG and AA vs. GG. In a stratified analysis by cancer type, significant association between Aurora-A V57I polymorphism and the decreased risk of breast cancer was identified in one genetic model: AA vs. GG. In a stratified analysis by ethnicity, in three genetic models, significant decreased cancer risk was observed among Caucasians (AA vs. GA+GG; AA vs. GG and A vs. G) instead of Asians. Furthermore, a stratified analysis by ethnicity in breast cancer subgroup, five genetic models (AA+GA vs. GG; AA vs. GA+GG; AA vs. GG; AA vs. GA and A vs. G), significant decreased cancer risk was observed among Caucasians, but not among Asians. A slight publication bias was observed in our meta-analysis, thus nonparametric “trim-and-fill” method was utilized to detect the stability of our results. The adjusted odds ratios and confidence intervals showed that Aurora-A V57I polymorphism might be a protective factor for cancer risk, suggesting the reliability of our findings.

Conclusion: In summary, this meta-analysis suggests that Aurora-A V57I polymorphism may be a protective factor for cancer risk.

Citation: Tang W, Qiu H, Jiang H, Wang L, Sun B, et al. (2014) Aurora-A V57I (rs1047972) Polymorphism and Cancer Susceptibility: A Meta-Analysis Involving 27,269 Subjects. PLoS ONE 9(3): e90328. doi:10.1371/journal.pone.0090328

Editor: Amanda Ewart Toland, Ohio State University Medical Center, United States of America

Received: November 29, 2013; Accepted: January 29, 2014; Published: March 5, 2014

Copyright: © 2014 Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported by Jiangsu University Clinical Medicine Science and Technology Development Fund (JLY20120004), Affiliated People’s Hospital of Jiangsu University Fund (Y200913) and National Natural Science Foundation of China (81370001, 81101889, 81000028) and Jiangsu Province Natural Science Foundation (BK2010333, BK2011481). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: xwk88915080@126.com (BS); haiyong_gu@hotmail.com (HG)

† These authors contributed equally to this work.
Materials and Methods

The meta-analysis is reported on the basis of the Preferred Reporting Items for Meta-analyses (PRISMA) guideline (Table S1. PRISMA checklist) [8].

Search Strategy

We searched genetic association articles on PubMed, EMBASE, CBM (Chinese BioMedical Disc) and CNKI (Chinese National Knowledge Infrastructure) databases (published up to June 01, 2013) using combinations of the following terms “Aurora-A”, “BTAK”, “AIKI”, “rs1047972”, “polymorphism”, “SNP”, “mutation”, “locus”, “cancer”, “carcinoma”, “tumor”, “neoplasm” and “malignance”. Additionally, in searching, the language of overall studies was restricted in English or Chinese. The references of retrieved publication, published reviews, letters and comments were scanned for additional relevant studies.

Inclusion and Exclusion Criteria

For inclusion in this meta-analysis, all eligible articles had to meet the major criteria: 1) focusing on the association of Aurora-A V57I polymorphism and cancer risk; 2) case-control or cohort study design; 3) frequencies of genotypes or alleles in case groups and control groups could be exacted from the articles; 4) genotype distributions of controls passed Hardy-Weinberg equilibrium (HWE) test; 5) all cases were diagnosed by pathological examination.

Exclusion criteria were: 1) overlapping data; 2) not case-control studies; 3) only relevant to oncotherapy; 4) review, meta-analysis or letter.

Data Extraction

In a standardized form, information from all original publications was extracted independently by two reviewers (W. Tang and H. Qiu). In case of disagreements, differences were adjudicated after elaborate discussion among all reviewers. For every eligible article, the following items were extracted: first author’s name, cancer type, publication year, country, ethnicity of study subjects, sample size (total cases and controls), genotype method, allele and genotype frequencies and evidence of HWE in controls.

Statistical analysis

An internet-based HWE test [http://ihg.gsf.de/cgi-bin/hw/hwa1.pl] was used to provide evidences of the HWE in the...
controls. STATA Version 12.0 software was used to calculate the crude odds ratio (OR) with the corresponding 95% confidence intervals (95% CI) to evaluate the strength of association between Aurora-A V57I polymorphism and cancer risk. Z test and \( P \) value (two-tailed) were used to evaluate the significance of the pooled OR, and if \( P < 0.05 \), statistically significance was confirmed. In current meta-analysis, a Chi-square based I\(^2\) test was applied to assess the potential heterogeneity among eligible publications, with I\(^2\) value less than 25% indicating low heterogeneity; 25% to 50% indicating moderate heterogeneity; and greater than 50% indicating high heterogeneity [9]. When I\(^2\) \( > 50\% \) or \( P > 0.10 \), the heterogeneity in publications was considered significant and the random-effects model (the DerSimonian-Laird method) was conducted for meta-analysis [10], otherwise, the fixed-effects model was applied (the Mantel-Haenszel method) [11]. Ethnicity-specific and cancer type-specific effect were evaluated by subgroup analysis (any type of cancer investigated by less than two case-control studies was combined into “other cancers”). The evidence of potential publication bias was evaluated by the funnel plot and Egger’s test. Publication bias was assessed by visual inspection an asymmetric plot. Additionally, statistical significance was considered at \( P > 0.1 \) for the interpretation of Egger’s test. Sensitivity

### Table 1. Characteristics of all included studies in the meta-analysis.

| Study          | Year | Ethnicity | Country | Cancer type  | Sample size (case/control) | Genotype method |
|----------------|------|-----------|---------|--------------|-----------------------------|-----------------|
| MARIE-GENICA   | 2009 | Caucasians | German  | breast cancer | 3139/5469                  | MALDI-TOF MS    |
| Dogan et al.   | 2008 | Caucasians | Turkish | lung cancer   | 102/102                     | Direct sequencing |
| Ye et al.      | 2008 | Caucasians | USA     | bladder cancer | 604/593                    | Taqman          |
| Chen et al.    | 2007 | Caucasians | USA     | colorectal cancer | 60/65                    | Direct sequencing |
| Wang et al.    | 2007 | Caucasians | USA     | lung cancer   | 1263/1154                  | TaqMan          |
| Milam et al.   | 2007 | Caucasians | USA     | uterine cancer | 140/188                    | Taqman          |
| Cox et al.     | 2006 | Caucasians | USA     | breast cancer | 1240/1724                  | TaqMan          |
| Ju et al.      | 2006 | Asians     | Korea   | gastric cancer | 501/427                    | MALDI-TOF MS    |
| Lo et al.      | 2005 | Asians     | China(Taiwan) | breast cancer | 704/1950                  | TaqMan          |
| DiCioccio et al. | 2004 | Caucasians | UK      | ovarian Cancer | 750/843                    | TaqMan          |
| DiCioccio et al. | 2004 | Caucasians | USA     | ovarian Cancer | 323/427                    | TaqMan          |
| DiCioccio et al. | 2004 | Caucasians | Denmark | ovarian Cancer | 432/1112                  | TaqMan          |
| Egan et al.    | 2004 | Caucasians | USA     | breast cancer | 905/788                    | Direct sequencing |
| Dai et al.     | 2004 | Asians     | China   | breast cancer | 1102/1188                  | TaqMan          |

MALDI–TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass spectrometry.

doi:10.1371/journal.pone.0090328.t001

### Table 2. Distribution of Aurora-A V57I polymorphism genotype and allele among cases and controls.

|          | Case | Control |          | Case | Control | HWE |
|----------|------|---------|----------|------|---------|-----|
|          | AA   | GA      | GG       | AA   | GA      | GG  | A  | G  | A  | G  |     |
| MARIE-GENICA | 69  | 580  | 2220  | 171  | 1561 | 3737 | 988 | 5290 | 1903 | 2053 | Yes |
| Dogan et al. | 5  | 33  | 64  | 5  | 25  | 72  | 43  | 161 | 35  | 169 | Yes |
| Ye et al. | 22  | 162  | 420  | 13  | 148  | 432 | 206 | 1002 | 174  | 1012 | Yes |
| Chen et al. | 1  | 20  | 39  | 2  | 20  | 43  | 22  | 98  | 24  | 106 | Yes |
| Wang et al. | 26  | 321  | 916  | 31  | 304  | 819 | 373 | 2153 | 366  | 1942 | Yes |
| Milam et al. | 3  | 31  | 106  | 5  | 45  | 138 | 37  | 243 | 55  | 321 | Yes |
| Cox et al. | 28  | 342  | 870  | 47  | 462  | 1215 | 398 | 2082 | 556  | 2892 | Yes |
| Ju et al. | 14  | 100  | 387  | 9  | 104  | 314 | 128 | 874 | 122  | 732 | Yes |
| Lo et al. | 15  | 146  | 543  | 30  | 414  | 1506 | 176 | 1232 | 474  | 3426 | Yes |
| DiCioccio et al.(UK) | 20  | 219  | 511  | 31  | 246  | 566 | 259 | 1241 | 308  | 1378 | Yes |
| DiCioccio et al.(USA) | 9  | 96  | 218  | 14  | 127  | 286 | 114 | 532 | 155  | 699 | Yes |
| DiCioccio et al.(Denmark) | 12  | 109  | 311  | 25  | 282  | 805 | 133 | 731 | 332  | 1892 | Yes |
| Egan et al. | 23  | 245  | 637  | 21  | 225  | 542 | 291 | 1519 | 267  | 1309 | Yes |
| Dai et al. | 16  | 281  | 805  | 17  | 263  | 908 | 313 | 1891 | 297  | 2079 | Yes |

HWE: Hardy–Weinberg equilibrium.

doi:10.1371/journal.pone.0090328.t002
analyses were conducted to evaluate the stability of the results. Nonparametric “trim-and-fill” method was also utilized to determine the stability of our results. All the statistical manipulations were implemented by using STATA 12.0 statistical software, and all the P values were two sided.

Results

Characteristics of eligible Studies

Relevant publications were retrieved from databases (PubMed, Embase, CBM and CNKI). As shown in Figure 1, a total of 151 relevant publications were adopted through reading literatures. Among them, 139 publications were excluded (24 for duplication of titles, seven for non-case-control studies, three for an association with cancer treatment, 99 for not relevant to Aurora-A V57I polymorphism and cancer risk, five reviews and one for overlapping data). After this step, 12 papers were identified for data extraction and assessment. After a manual search of the bibliography lists from retrieved, as a result, another two articles were recruited (Figure 1). Afterwards, two papers were discarded because the genetic distributions in the control group statistically deviated from HWE [12,13]. In the study reported by DiCioccio and colleagues [14], there were three independent groups, thus we treated them separately. Lastly, 14 case-control studies [6,7,14–23] on the association between the Aurora-A V57I (rs1047972) polymorphism and cancer risk were recruited in this meta-analysis. Among 14 studies [6,7,14–23], five investigated breast cancer [6,7,15,16,21], three investigated ovarian cancer [14], two investigated lung cancer and the others investigated bladder cancer, uterine cancer, gastric cancer and colorectal cancer [14,17–20,22,23]. Among these studies, three were from Asians [15–17] and 11 from Caucasians [6,7,14,18–23]. Characteristics of studies extracted and included in this meta-analysis are exhaustive summarized in Table 1, Aurora-A V57I genotype and allele frequencies among cancer cases and controls were presented in Table 2.

Quantitative Synthesis

In total, our meta-analysis involved 11,245 cancer cases and 16,024 controls from 14 eligible investigations. Our findings demonstrated a borderline association between Aurora-A V57I...
polymorphism and decreased risk of cancer in two genetic models: AA vs. GA+GG (OR, 0.87; 95% CI, 0.74–1.02; \(P = 0.091\)) and AA vs. GG (OR, 0.87; 95% CI, 0.74–1.02; \(P = 0.077\)) (Table 5). In a stratified analysis by cancer type, we found significant association between Aurora-A V57I polymorphism and decreased risk of breast cancer in one genetic model: AA vs. GG (OR, 0.81; 95% CI, 0.66–0.99; \(P = 0.043\)) (Table 4). In a stratified analysis by ethnicity, we found significant decreased cancer risk in three genetic models (OR, 0.82; 95% CI, 0.69–0.98; \(P = 0.025\) for AA vs. GA+GG; OR, 0.81; 95% CI, 0.69–0.97; \(P = 0.020\) for AA vs. GG and OR, 0.95; 95% CI, 0.90–1.00; \(P = 0.035\) for A vs. G) in Caucasians, but not in Asians (Table 3, Figure 2). Additionally, a stratified analysis by ethnicity was conducted in breast cancer subgroup. We found significant decreased cancer risk in five genetic models (OR, 0.92; 95% CI, 0.86–1.00; \(P = 0.043\) for AA+GA vs. GG; OR, 0.75; 95% CI, 0.60–0.94; \(P = 0.014\) for AA vs. GA+GG; OR, 0.74; 95% CI, 0.59–0.93; \(P = 0.009\) for AA vs. GG; OR, 0.79; 95% CI, 0.62–0.99; \(P = 0.042\) for AA vs. GA; and OR, 0.92; 95% CI, 0.86–0.98; \(P = 0.011\) for A vs. G) in Caucasians, but not in Asians (Table 5).

Tests for Publication Bias, Sensitivity Analyses, and Heterogeneity

Begg’s funnel plot and Egger’s test were carried out to measure publication bias. The shape of funnel plot revealed the evidence of funnel plot symmetry (Figure 3). The statistical results indicated that there was a slight publication bias in this meta-analysis (A vs. G: Begg’s test \(P = 0.511\), Egger’s test \(P = 0.113\); AA vs. GG: Begg’s test \(P = 0.443\), Egger’s test \(P = 0.083\); GA vs. GG: Begg’s test \(P = 0.324\), Egger’s test \(P = 0.271\); AA vs. GA: Begg’s test \(P = 0.324\), Egger’s test \(P = 0.190\); dominant model: Begg’s test \(P = 0.384\), Egger’s test \(P = 0.170\); recessive model: Begg’s test \(P = 0.511\), Egger’s test \(P = 0.103\)).

An individual study involved in the meta-analysis was omitted in turn, to confirm the influence of individual dataset to the pooled ORs, and the statistical significances of all genetic comparison models were not qualitatively altered (Figure 4) (data not shown). Nonparametric “trim-and-fill” method was utilized as the other sensitivity analysis method. The adjusted ORs and CIs showed that Aurora-A V57I polymorphism may be a protective factor for cancer risk (A vs. G: adjusted pooled OR = 0.92; 95% CI: 0.88–0.96; \(P = 0.000\); AA vs. GG: adjusted pooled OR = 0.76; 95% CI: 0.66–0.85; \(P = 0.000\); dominant model: adjusted pooled OR = 0.94; 95% CI: 0.89–0.98; \(P = 0.010\); recessive model: adjusted pooled OR = 0.76; 95% CI: 0.66–0.88; \(P = 0.000\); GA vs. GG: adjusted pooled OR = 0.95; 95% CI: 0.90–1.00; \(P = 0.041\); AA vs. GA: adjusted pooled OR = 0.89; 95% CI: 0.76–1.05; \(P = 0.174\) (Figure 5).

The results showed there were relatively low heterogeneities among the recruited studies. Since tumor origin and ethnicity might influence the results of meta–analysis, we implemented subgroup analyses by cancer type and ethnicity (Table 3 and Table 4). The results indicated that breast cancer, lung cancer, Asian populations might contribute to the heterogeneity.

**Discussion**

Recently, many studies have indicated that genovariation plays a crucial role in individual susceptibility to complex disease, such as cancer and autoimmune disease [24,25]. Functional polymorphisms, which impact on the regulation of gene expression, can lead to differences between individuals in the risk to multiple cancers [26]. Early studies have demonstrated that Aurora-A is an oncogene situated on chromosome 20q13.2, a region constantly amplified in a number of human cancers [27–29]. Recent investigations have showed that regulated Aurora-A is pivotal for

| Polymorphism | Genetic comparison | Population | OR(95%CI); \(P\) | Test of heterogeneity |
|--------------|-------------------|------------|------------------|---------------------|
|              |                   |            | \(p\)-Value, I\(^2\) | Model               |
| AA+GA vs. GG | All                | 0.97(0.92–1.02);0.252 | 0.375,7.0% | F                   |
|              | Asians             | 1.02(0.84–1.25);0.839 | 0.098,57.0% | R                   |
|              | Caucasians         | 0.95(0.90–1.01);1.07 | 0.677,0.0% | F                   |
| AA vs. GA+GG | All                | 0.87(0.74–1.02);0.091 | 0.591,0.0% | F                   |
|              | Asians             | 1.23(0.82–1.85);0.316 | 0.783,0.0% | F                   |
|              | Caucasians         | 0.82(0.69–0.98);0.025 | 0.676,0.0% | F                   |
| AA vs. GG    | All                | 0.87(0.74–1.02);0.077 | 0.526,0.0% | F                   |
|              | Asians             | 1.23(0.82–1.86);0.316 | 0.853,0.0% | F                   |
|              | Caucasians         | 0.81(0.69–0.97);0.020 | 0.595,0.0% | F                   |
|              |                    |            |                   |                     |
| Aurora-A V57I| GA vs. GG          | All        | 0.98(0.93–1.03);0.445 | 0.519,0.0% | F                   |
|              | Asians             | 1.00(0.79–1.25);0.97 | 0.055,65.6% | R                   |
|              | Caucasians         | 0.97(0.91–1.03);0.278 | 0.859,0.0% | F                   |
| AA vs. GA    | All                | 0.89(0.75–1.05);0.158 | 0.730,0.0% | F                   |
|              | Asians             | 1.23(0.81–1.87);0.332 | 0.491,0.0% | F                   |
|              | Caucasians         | 0.84(0.70–1.00);0.054 | 0.862,0.0% | F                   |
| A vs. G      | All                | 0.96(0.92–1.01);0.128 | 0.273,16.5% | F                   |
|              | Asians             | 1.06(0.94–1.18);0.351 | 0.221,33.7% | F                   |
|              | Caucasians         | 0.95(0.90–1.00);0.035 | 0.479,0.0% | F                   |

F indicates fixed model; R indicates random model.

doi:10.1371/journal.pone.0090328.t003

Table 3. Different comparative genetic models results of this meta-analysis in the subgroup analysis by race.
maintenance of chromosome integrity after DNA damage, and Aurora-A polymorphisms affect some important functions of Aurora-A protein [30]. Some investigations have demonstrated that Aurora-A gene SNPs may associate with the production of the Aurora-A protein on the process of carcinogenesis [31,32]. In decade, several molecular epidemiological studies have been performed to assess the association of Aurora-A V57I (rs1047972 G>A) polymorphism with cancer risk. However, the results were conflicting. Thus, we conducted a comprehensive meta-analysis involving published data, to assess the strength of association between Aurora-A V57I polymorphism and cancer risk. In current meta-analysis, a total of independent 14 case-control studies in 12 publications including 11,245 cases and 16,024 controls were recruited, and then identified the association of Aurora-A V57I polymorphism with cancer risk. Our results demonstrated a borderline association between the Aurora-A V57I polymorphism and decreased risk of cancer in two genetic models: AA vs. GA+GG and AA vs. GG. In a stratified analysis by cancer type, our results indicated that Aurora-A V57I polymorphism was associated with a significantly decreased risk of breast cancer in AA vs. GG genetic model. In a stratified analysis by ethnicity, a protective effect of Aurora-A V57I polymorphism was observed in Caucasians, but not in Asians. In addition, in a stratified analysis by ethnicity in breast cancer subgroup, five genetic models significant decreased cancer risk were observed among Caucasians (AA+GA vs. GG; AA vs. GA+GG; AA vs. GG; AA vs. GA and A vs. G), but not among Asians.

It has been observed that the Aurora-A F31I polymorphism, converts the activity of the Aurora-A box-1, leading to obstruction of p53 binding and reducing the degradation of Aurora-A [1]. The stable overexpression of Aurora-A results in centrosome amplification, chromosomal instability and promotion of tumorigenesis [1]. Aurora-A V57I polymorphism, which results in a valine (val) to isoleucin (Ile) substitution at codon 57, is associated with subdued cellular transformation and increased chromosomal stability. The Aurora-A V57I polymorphism in Aurora-A box-2 does not regulate Aurora-A degradation, but may affect the secondary structure and function of Aurora-A F31I polymorphism [6].

| Polymorphism | Genetic comparison | Cancer type | OR(95%CI); P | Test of heterogeneity (p-Value, I²) | Model |
|--------------|---------------------|-------------|-------------|------------------------------------|-------|
| AA+GA vs. GG | All                 | AA vs. GG  | 0.97(0.92–1.02);0.252 | 0.375,7.0% | F |
|              | Breast cancer       | 0.99(0.89–1.10);0.841 | 0.085,11.1% | R |
|              | Ovarian Cancer      | 0.98(0.85–1.13);0.792 | 0.925,0.0% | F |
|              | Lung cancer         | 0.96(0.81–1.14);0.642 | 0.167,47.6% | F |
|              | Other cancers       | 1.00(0.84–1.19);0.991 | 0.313,15.7% | F |
| AA vs. GA+GG | All                 | AA vs. GG  | 0.87(0.74–1.02);0.091 | 0.591,0.0% | F |
|              | Breast cancer       | 0.82(0.67–1.00);0.054 | 0.326,13.9% | F |
|              | Ovarian Cancer      | 0.88(0.59–1.30);0.518 | 0.487,0.0% | F |
|              | Lung cancer         | 0.79(0.49–1.29);0.349 | 0.698,0.0% | F |
|              | Other cancers       | 1.36(0.84–2.21);0.216 | 0.693,0.0% | F |
| AA vs. GG    | All                 | AA vs. GG  | 0.87(0.74–1.02);0.077 | 0.526,0.0% | F |
|              | Breast cancer       | 0.82(0.67–1.00);0.054 | 0.326,13.9% | F |
|              | Ovarian Cancer      | 0.88(0.59–1.30);0.518 | 0.487,0.0% | F |
|              | Lung cancer         | 0.79(0.49–1.29);0.349 | 0.698,0.0% | F |
|              | Other cancers       | 1.36(0.84–2.21);0.216 | 0.693,0.0% | F |
| Aurora-A V57I| GA vs. GG           | All         | 0.98(0.93–1.03);0.445 | 0.519,0.0% | F |
|              | Breast cancer       | 0.98(0.91–1.05);0.508 | 0.145,41.5% | F |
|              | Ovarian Cancer      | 0.99(0.86–1.15);0.915 | 0.996,0.0% | F |
|              | Lung cancer         | 0.98(0.82–1.17);0.816 | 0.169,47.1% | F |
|              | Other cancers       | 1.35(0.83–2.21);0.225 | 0.661,0.0% | F |
| AA vs. GA    | All                 | AA vs. GA  | 0.89 (0.75–1.05);0.158 | 0.730,0.0% | F |
|              | Breast cancer       | 0.84(0.68–1.04);0.103 | 0.465,0.0% | F |
|              | Ovarian Cancer      | 0.88(0.59–1.33);0.552 | 0.524,0.0% | F |
|              | Lung cancer         | 0.79(0.48–1.31);0.357 | 0.949,0.0% | F |
|              | Other cancers       | 1.40(0.84–2.31);0.197 | 0.748,0.0% | F |
| AA vs. GA    | All                 | AA vs. GA  | 0.96 (0.92–1.01);0.128 | 0.273,16.5% | F |
|              | Breast cancer       | 0.98(0.89–1.08);0.749 | 0.062,55.4% | R |
|              | Ovarian Cancer      | 0.97(0.86–1.10);0.663 | 0.770,0.0% | F |
|              | Lung cancer         | 0.95 (0.82–1.10);0.485 | 0.202,38.6% | F |
|              | Other cancers       | 1.03(0.88–1.20);0.699 | 0.313,15.7% | F |

F indicates fixed model; R indicates random model.
doi:10.1371/journal.pone.0090328.t004
demonstrated that the V57I mutation in Aurora-A decreased the risk of cancer, perhaps by modifying the function of Aurora-A F31I polymorphism and altering the secondary structure of protein. Since cancer origins might affect the outcomes from meta-analysis, we performed a stratified analysis by cancer type for Aurora-A V57I polymorphism. The results indicated that Aurora-A V57I polymorphism was associated with a decreased risk of breast cancer, but not of ovarian cancer, lung cancer and other cancers.

However, our results should be interpreted with very caution. Only five case-control studies for breast cancer, three for ovarian cancer and two for lung cancer were included in this meta-analysis, which might reduce statistical power to get a reliable result. Future, more large-scale studies should be conducted to confirm or refute these results. Because ethnicity could also affect the results of meta-analysis, we performed a stratified analysis by race for Aurora-A V57I polymorphism. Our results demonstrated

Table 5. Different comparative genetic models results of this meta-analysis in the breast cancer subgroup analysis by ethnicity.

| Polymorphism       | Genetic comparison | Population | OR(95% CI); P       | Test of heterogeneity |
|--------------------|--------------------|------------|---------------------|-----------------------|
|                    |                    |            | OR(95% CI); P       | (p-Value, I²)         | Model |
| AA+GA vs. GG       | All                | 0.99(0.89–1.10);0.841 | 0.085,51.1% | R |
|                    | Asians             | 1.10(0.96–1.27);0.158 | 0.222,32.9% | F |
|                    | Caucasians         | 0.92(0.86–1.00);0.043 | 0.403,0.0%  | F |
| AA vs. GA+GG       | All                | 0.82(0.67–1.00);0.054 | 0.326,13.9% | F |
|                    | Asians             | 1.20(0.75–1.91);0.441 | 0.504,0.0%  | F |
|                    | Caucasians         | 0.75(0.60–0.94);0.014 | 0.600,0.0%  | F |
| AA vs. GG          | All                | 0.81(0.66–0.99);0.043 | 0.277,21.6% | F |
|                    | Asians             | 1.22(0.77–1.95);0.396 | 0.574,0.0%  | F |
|                    | Caucasians         | 0.74(0.59–0.93);0.009 | 0.565,0.0%  | F |
| Aurora-A V57I      | GA vs. GG          | All                | 0.98(0.91–1.05);0.508 | 0.145,41.5% | F |
|                    | Asians             | 1.10(0.95–1.26);0.205 | 0.154,50.7% | F |
|                    | Caucasians         | 0.94(0.87–1.02);0.147 | 0.463,0.0%  | F |
| AA vs. GA          | All                | 0.84(0.68–1.04);0.103 | 0.465,0.0%  | F |
|                    | Asians             | 1.13(0.70–1.83);0.614 | 0.329,0.0%  | F |
|                    | Caucasians         | 0.79(0.62–0.99);0.042 | 0.679,0.0%  | F |
| A vs. G            | All                | 0.98 (0.89–1.08);0.749 | 0.062,55.4% | R |
|                    | Asians             | 1.10(0.97–1.25);0.139 | 0.369,0.0%  | F |
|                    | Caucasians         | 0.92(0.86–0.98);0.011 | 0.376,0.0%  | F |

F indicates fixed model; R indicates random model.

Figure 3. For Aurora-A V57I polymorphism, Begg’s funnel plot analysis for publication bias for overall cancer in the dominant model.

doi:10.1371/journal.pone.0090328.g003
the *Aurora-A* V57I polymorphism was a protective factor in Caucasians but not in Asians. In current meta-analysis, only three investigations of Asians were obtained. The outcomes might be due to fluke because the limited number of eligible studies and sample sizes might lead to deficient statistical power to measure a minor effect. Thus, our results should also be interpreted with very caution. In the future, further studies with large sample sizes regarding Asians should be carried out to identify the possible effects of *Aurora-A* V57I polymorphism ethnic variations on cancer risk.

Two significant issues, heterogeneity and publication bias, should be addressed. A slight publication bias and relatively low heterogeneity were observed in our meta-analysis. As subgroup analyses were performed according to ethnicity and cancer type, Asian populations, lung cancer and breast cancer subgroups contributed the major source of heterogeneity. Since publication bias was observed, nonparametric “trim-and-fill” method was utilized to detect the stability of our results. The adjusted ORs and CIs show that *Aurora-A* V57I polymorphism may be a protective factor for cancer risk, suggesting the reliability of our findings.

Although our results were stable and suggestive, there were several limitations in this study which should be acknowledged. First, only 14 eligible case-control studies in 12 publications were recruited in this meta-analysis; therefore, the results might be a fluke, as the limited number and sample sizes of eligible studies could lead to deficient statistical power to detect a real influence. Second, all eligible case-control studies were from Asians and Caucasians; thus, our results only proper for these two populations.

![Figure 4. Sensitivity analysis of the influence of dominant model in overall cancer meta–analysis (fixed–effects estimates).](doi:10.1371/journal.pone.0090328.g004)

![Figure 5. Filled funnel plot of meta-analysis of between the *Aurora-A*V57I polymorphism and EC risk (AA+GA vs. GG).](doi:10.1371/journal.pone.0090328.g005)
Third, a slight publication bias was observed in our meta-analysis. Only twelve eligible publications were recruited in current meta-analysis, so some unpublished studies were unavoidably missed, which might result in bias. Fourth, high heterogeneity existed in some subgroups. This could be due to other differences between publications, such as age, gender, cancer type, ethnicity, smoking, drinking, other lifestyle factors, environmental risk factors and unscreened controls as well. For limited number of eligible studies or lack of sufficient information in a uniform criterion in investigations, these factors were not considered. Fifth, the Aurora-A V571 and F31I polymorphism locate on the same Aurora-A exon and significant linkage disequilibrium was found between the two coding SNPs, given the V571 polymorphism might play an important role in the process of carcinogenesis though altering the secondary structure and function of Aurora-A F31I polymorphism, thus, this important SNP, Aurora-A F31I, should not be ignored. Sixth, in this meta-analysis, some cancers only had one study included; therefore, any type of cancer investigated by less than two case-control studies was combined into “other cancers”, which might lead to heterogeneity in this subgroup.

In conclusion, this meta-analysis indicates that the Aurora-A V571I polymorphism may be a protective factor for cancer risk, especially, in Caucasians and breast cancer. As only 14 studies were recruited in this meta-analysis and current evidence was limited, in the future, more large-scale studies with an adequate methodological quality and properly controlling should be carried out, to confirm or refute the relationship between Aurora-A V571I polymorphism and the risk of cancer.

Supporting Information

Checklist S1 PRISMA checklist, Checklist of items to include when reporting a systematic review or meta-analysis (diagnostic review consisting of cohort studies). (DOCX)

Author Contributions

Conceived and designed the experiments: HG BS. Performed the experiments: WT HQ HJ. Analyzed the data: WT HQ HJ BS LW HG. Contributed reagents/materials/analysis tools: HG BS. Wrote the paper: WT HQ HJ.

References

1. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, et al. (2003) Identification of S6k1/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34: 403–412.
2. Fu J, Bian M, Jiang Q, Zhang C (2007) Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 5: 1–10.
3. Hirota T, Kunitoki N, Sasaayama T, Marumoto T, Zhang D, et al. (2003) Aurora-A and an activating activator, the LIM protein Alj9a, are required for mitotic commitment in human cells. Cell 114: 585–598.
4. Do J, Jablonski S, Yen TJ, Hannon GJ (2008) Atrix regulates Aurora-A localization. Biochem Biophys Res Comm 370: 213–219.
5. Chen J, Li D, Wei C, Sen S, Killary AM, et al. (2007) Aurora-A and p16 polynorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 13: 3100–3104.
6. Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, et al. (2004) STK15 polymorphism and breast cancer risk in a population-based study. Cancer Genet Cytogenet 25: 2149–2153.
7. Risk M-GG/GSMSMT/BRB (2010) Polymorphisms in the BRCA1 and ABCB1 genes mediate membrane hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120: 727–736.
8. Mohor D, Liberec A, Tezli MA, Altmann DG, Group F (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264–269, W264.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
11. Mantel N HW (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
12. Kimura MT, Mori T, Conroy J, Nowak NJ, Satomi S, et al. (2005) Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res 65: 3548–3554.
13. Chen L (2005) Genetic polymorphisms and disease risks: STK5 gene and risk for gastric cancer, MMP9 gene and risk for Thoracic Aortic Aneurysm and Thoracic Aortic Dissection: China Medical University. 101 p.
14. Dicicacca RA, Song H, Waterfall C, Kimura MT, Nagase H, et al. (2004) STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 13: 1599–1594.
15. Lo YL, Yu JC, Chen ST, Yang HC, Fann CS, et al. (2005) Breast cancer risk associated with genotypic polymorphism of the mitosis-regulating gene Aurora-A/STK15/BEAK. Int J Cancer 115: 276–283.
16. Dai C, Gai Q, Shu XO, Ewart-Toland A, Wen WQ, et al. (2004) Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13: 2063–2070.
17. Ju H, Cho H, Kim WS, Kim WH, Iman C, et al. (2006) Functional polymorphism 57Val>Be of aurora kinase A associated with increased risk of gastric cancer progression. Cancer Lett 242: 273–279.
18. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. (2008) Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112: 2467–2474.
19. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, et al. (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13: 5974–5981.
20. Milam MR, Gu J, Yang H, Celestino J, WU W, et al. (2007) STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. Gynecol Oncol 107: 71–74.
21. Cox DG, Hankinson SE, Hunter DJ (2006) Polymorphisms of the AURKA (STK15/Aurora Kinase) Gene and Breast Cancer Risk (United States). Cancer Causes Control 17: 81–83.
22. Dogan I, Ekmakci A, Yurdakul AS, Ozen IH, Ozuturk C, et al. (2006) Polymorphisms in the aurora-a gene is not associated with lung cancer in the Turkish population. DNA Cell Biol 27: 443–448.
23. Chen J, Sen S, Amos CI, Wei C, Jones JS, et al. (2007) Association between Aurora-A kinase polymorphisms and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Mol Cancer 86: 249–256.
24. Gast A, Bermejo JL, Cura S, Brandt A, Weires M, et al. (2011) Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One 6: e24370.
25. Pessone C, Caracci C, Ceccherelli B, Di Fusco D, Spinelli FR, et al. (2013) TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics.
26. Ye S (2000) Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19: 623–629.
27. Baba Y, Nosho K, Shimak I, Irahara N, Kure S, et al. (2009) Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia 11: 418–425.
28. LentinI L, Amato A, Schillaci T, Di Leonardo A (2007) Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype. BMC Cancer 7: 212.
29. Losmann S, Shen Y, Jotting U, Wiesle P, Walch A, et al. (2007) Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 13: 4083–4091.
30. Pan JV, Ajani JA, Gu J, Gong Y, Quin A, et al. (2012) Association of Aurora-A/STK15 kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. Cancer 118: 4346–4353.
31. Ruan Y, Song AP, Wang H, Xie YT, Han JY, et al. (2011) Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population. J Pathol 225: 535–543.
32. Tsatsuka M, Sano S, Kajiyama S, Suto S, Kasai H, et al. (2005) Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 24: 1122–1127.